Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure

Journal of the American Society of Nephrology

Volumn 15, Issue 7, 2004, Pages 1877-1882

  Cooper, Angela ^a   Mikhail, Ashraf ^a   Lethbridge, Mark W ^a   Kemeny, D Michael ^a   Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEMOGLOBIN; PENTOXIFYLLINE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFICACY; ERYTHROPOIESIS; FEMALE; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 3042663307     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000131523.17045.56     Document Type: Article

References (33)

1. Drueke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16[Suppl 7]: 25-28, 2001
2. Stenvinkel P: The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16[Suppl 7]: 36-40, 2001
3. Macdougall IC, Cooper A: The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 17[Suppl 1]: 48-52, 2002
4. Means RT Jr, Dessypris EN, Krantz SB: Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 150: 59-64, 1992
5. Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of IFN-gamma and TNF-alpha. J Invest Med 47: 204-211, 1999
6. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC: Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 14: 1776-1784, 2003
7. Frampton JE, Brogden RN: Pentoxifylline (oxpentifylline): A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 7: 480-503, 1995
8. Semmler J, Gebert U, Eisenhut T, Moeller J, Schonharting MM, Allera A, Endres S: Xanthine derivatives: Comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78: 520-525, 1993
9. Mandell GL: Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol 25[Suppl 2]: S20-S22, 1995
10. Benbernou N, Esnault S, Potron G, Guenounou M: Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 25[Suppl 2]:S75-S79, 1995
11. Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP: Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 25[Suppl 2]: S80-S84, 1995
12. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P: Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351: 1091-1093, 1998
13. MacDonald MJ, Shahidi NT, Allen DB, Lustig RH, Mitchell TL, Cornwell ST: Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus. JAMA 271: 27-28, 1994
14. Calderon MJ, Landa N, Aguirre A, Diaz-Perez JL: Successful treatment of cutaneous PAN with pentoxifylline. Br J Dermatol 128: 706-708, 1993
15. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A: Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med 124: 891-893, 1996
16. Nurnberg W, Grabbe J, Czarnetzki BM: Synergistic effects of pentoxifylline and dapsone in leucocytoclastic vasculitis. Lancet 343: 491, 1994
17. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS: An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 22: 625-629, 1995
18. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C, Knobler R, Schwarz A, Luger TA, Schwarz T: Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83: 262-267, 1994
19. Jung T, Schauer U, Heusser C, Neumann C, Rieger C: Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159: 197-207, 1993
20. Prussin C, Metcalfe DD: Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 188: 117-128, 1995
21. Freitas JP, Filipe PM: Pentoxifylline: A hydroxyl radical scavenger. Biol Trace Elem Res 47: 307-311, 1995
22. Belloc F, Jaloustre C, Dumain P, Lacombe F, Lenoble M, Boisseau MR: Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 25[Suppl 2]: S71-S74, 1995
23. Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA, Fresno M: Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 299: 753-759, 2001
24. Fleming CM, He H, Ciota A, Perkins D, Finn PW: Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness. J Immunol 167: 1703-1711, 2001
25. Dai CH, Price JO, Brunner T, Krantz SB: Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 91: 1235-1242, 1998
26. Means RT Jr, Krantz SB: Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 91: 416-419, 1993
27. Means RT Jr: Recent developments in the anemia of chronic disease. Curr Hematol Rep 2: 116-121, 2003
28. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD: Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: Improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100: 474-482, 2002
29. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM: Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206: 388-390, 2003
30. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 48: 2122-2127, 2003
31. Cooper AC, Breen CP, Vyas B, Ochola J, DMK, ICM: Poor response to recombinant erythropoietin is associated with loss of T lymphocyte CD28 expression and altered interleukin-10 production. Nephrol Dial Transplant 18: 133-140, 2003
32. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63: 1908-1914, 2003
33. Silverberg DS, Wexler D, Blum B, Iaina A: Anemia in chronic kidney disease and congestive heart failure. Blood Purif 21: 124-130, 2003